LPTN or L Path Website has what the Company is working on and the only thing ready to go is the Macular Degeneration Application. Everything else stated on the Website is Years Away as far as pre-clinical studies, Phase 1, etc development is concerned. If they were able to do all the stuff posted, the stock would not be under 30 cents and they would have $100 Million in Cash instead of Less than 10 Million in Cash. The Conference call, whose content should be found on their website, discussed MOSTLY that, the MD stuff. LPTN overall is a long term or near term Patience Play with some bounce spikes in it for short term Momentum Players. So money can be made either way. Biggest near term run will be IF they announce some Heavy hitting Pharma Partners like Pfizer, etc, for the MD product.
Good Trading to All
